3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
28
HER2-positive Breast Cancer
4
Neoplasms
3
Multiple Myeloma
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Brain Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Salivary Gland Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma
1
Interventions
ruxolitinib
9
fludarabine phosphate
8
fludarabine
8
Whole-Body Irradiation
8
Specimen Handling
7
Cytarabine
7
Cyclophosphamide
7
Mycophenolic Acid
6
Tacrolimus
5
Injections
5
Busulfan
5
Biopsy
5
Azacitidine
5
Stem Cell Transplantation
4
Sirolimus
4
Peripheral Blood Stem Cell Transplantation
4
Melphalan
4
Granulocyte Colony-Stimulating Factor
4
CPX-351
4
venetoclax
3
luspatercept
3
decitabine and cedazuridine drug combination
3
Liposomes
3
Idarubicin
3
Daunorubicin
3
Cyclosporine
3
Blood Specimen Collection
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
selinexor
2
nilotinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
pertuzumab
×
90 days
×
Clear all
No trials found.